0001209191-19-035510.txt : 20190607 0001209191-19-035510.hdr.sgml : 20190607 20190607160510 ACCESSION NUMBER: 0001209191-19-035510 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190603 FILED AS OF DATE: 20190607 DATE AS OF CHANGE: 20190607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reiter Sarah CENTRAL INDEX KEY: 0001734605 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37383 FILM NUMBER: 19885708 MAIL ADDRESS: STREET 1: 202 COUSTEAU PLACE CITY: DAVIS STATE: CA ZIP: 95618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 200 CITY: DAVIS STATE: X1 ZIP: 95618 BUSINESS PHONE: 602-429-0471 MAIL ADDRESS: STREET 1: 4222 E. THOMAS RD STREET 2: SUITE 320 CITY: PHOENIX STATE: X1 ZIP: 85018 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-03 0 0001469443 Arcadia Biosciences, Inc. RKDA 0001734605 Reiter Sarah C/O ARCADIA BIOSCIENCES, INC. 202 COUSTEAU PLACE, SUITE 105 DAVIS CA 0 1 0 0 Chief Commercial Officer Stock Option (right to buy) 5.04 2019-06-03 4 A 0 23305 0.00 A 2029-06-03 Common Stock 23305 71705 D The Option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or June 3, 2020, with the remaining 75% vesting in 36 equal installments beginning June 30, 2020 and ending May 31, 2023, subject to the Participant's continued service. Sarah Reiter, by Attorney-in-Fact, Sheila Khayami 2019-06-07 EX-24 2 attachment1.htm EX-24 DOCUMENT
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and
appoints each of Matthew Plavan, Pamela Haley, and Sheila Khayami, signing
singly, the undersigned's true and lawful attorney-in-fact to:
(i)	execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Arcadia Biosciences, Inc. (the
"Company"), Forms 3, 4 and 5  (including amendments thereto), and for the
purpose of filing such Forms, to execute and deliver any documents
necessary to the Securities and Exchange Commission ("SEC") for the
purpose of obtaining EDGAR codes, all in accordance with Section 16(a) of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and
the rules and regulations promulgated thereunder;
(ii)	do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to complete and execute any such Forms 3, 4
or 5 and timely file such form (including amendments thereto) with the SEC and
any stock exchange or similar authority; and
(iii)	take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution and revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.

The undersigned acknowledges that the foregoing attorney-in-fact, in serving in
such capacity at the request of the undersigned, is not assuming nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.

The undersigned agrees that such attorney-in-fact may rely entirely on
information furnished orally or in writing by the undersigned to such
attorney-in-fact.  The undersigned also agrees to indemnify and hold harmless
the Company and such attorney-in-fact against any losses, claims, damages or
liabilities (or actions in these respects) that arise out of or are based on
any untrue statement or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4 or 5 (including amendments
thereto) and agrees to reimburse the Company and such attorney-in-fact for any
legal or other expenses reasonably incurred in connection with investigating or
defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier (a) revoked by the undersigned in a signed writing delivered to
the foregoing attorney-in-fact or (b) superseded by a new power of attorney
regarding the purposes outlined in the first paragraph hereof as of a later
date.


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 8th day of February 2019.

/s/ Sarah Reiter
Sarah Reiter